Risperdal vs. Invega
See how Risperdal and Invega compare on approved uses, dosing, side effects, and cost.
Key Takeaways
Risperdal and Invega are both atypical antipsychotics, and Invega's active ingredient is actually the metabolite Risperdal breaks down into in the body.
Risperdal needs a titration step before reaching its maintenance dose, while Invega's extended-release tablet is taken at a fixed dose from day one.
Risperdal covers bipolar disorder and pediatric autism-related irritability, while Invega's FDA approval is limited to schizophrenia and schizoaffective disorder.
Risperdal vs. Invega Drug Summary
Risperdal
Risperdal (risperidone) is an atypical antipsychotic approved for schizophrenia, acute manic or mixed episodes of bipolar I disorder, and irritability linked to autistic disorder in children. It comes as a tablet, oral solution, or orally disintegrating tablet, and treatment usually starts at 2 mg once daily before moving to a maintenance dose of 4 mg to 8 mg.
Invega
Invega (paliperidone) is an atypical antipsychotic approved for schizophrenia and schizoaffective disorder in adults. It is taken as a once-daily extended-release tablet at a fixed dose between 3 mg and 12 mg, with no titration period needed.
Risperdal vs. Invega Side Effects
Risperdal
Invega
Risperdal vs. Invega Dosage
Risperdal
Invega
| STAGE | DOSE | WHEN |
| Starting dose | 2 mg once daily | Day 1 |
| Maximum dose | 2 mg once daily | Same as starting |
| Dose changes | None | Fixed dose |
| STAGE | DOSE | WHEN |
| Starting dose | 6 mg once daily | At the start |
| Maximum dose | 12 mg once daily | If needed |
| Dose changes | 3 increases | As tolerated |
Risperdal
| STAGE | DOSE | WHEN |
| Starting dose | 2 mg once daily | Day 1 |
| Maximum dose | 2 mg once daily | Same as starting |
| Dose changes | None | Fixed dose |
Invega
| STAGE | DOSE | WHEN |
| Starting dose | 6 mg once daily | At the start |
| Maximum dose | 12 mg once daily | If needed |
| Dose changes | 3 increases | As tolerated |
Risperdal vs. Invega Indications
Risperdal
Risperdal is FDA-approved for schizophrenia, acute manic or mixed episodes of bipolar I disorder, and irritability associated with autistic disorder in children and adolescents. It is also used off-label for OCD augmentation and for tic disorders like Tourette syndrome.
Schizophrenia in adults and adolescents (13-17 years)
Acute manic or mixed episodes of Bipolar I Disorder
Irritability associated with autistic disorder in children
Off-label: OCD augmentation and tic disorders/Tourette syndrome
Invega
Invega is FDA-approved for schizophrenia in adults and adolescents, and for schizoaffective disorder in adults, either alone or alongside mood stabilizers or antidepressants. It is not approved for bipolar disorder or pediatric irritability, unlike Risperdal.
Schizophrenia in adults and adolescents (12-17 years)
Schizoaffective disorder as monotherapy
Schizoaffective disorder adjunct to mood stabilizers/antidepressants
Not approved for bipolar disorder or dementia-related psychosis
Risperdal vs. Invega Pros and Cons
Risperdal
Risperdal has a broader set of FDA-approved uses, covering bipolar disorder and pediatric autism-related irritability in addition to schizophrenia. It has been on the market since 1993, giving prescribers decades of real-world experience with its dosing and side effect profile.
Pros
FDA-approved for bipolar disorder and autism-related irritability, not just schizophrenia
Available as tablet, oral solution, and orally disintegrating tablet for flexible dosing
Decades of clinical use since 1993 with well-established side effect data
Roughly $185 to $625 per month without insurance, generally lower than Invega
Cons
Requires a titration step before reaching the maintenance dose
Higher reported rates of insomnia and somnolence based on its own label
Pediatric schizophrenia approval starts at age 13, a year later than Invega
Only available in oral forms, with no long-acting injectable under this brand
Invega
Invega's extended-release tablet delivers a steady dose without a titration period, and its long-acting injectable versions offer monthly, every-3-month, or every-6-month dosing for patients who struggle with daily pills. Its FDA approval is narrower, limited to schizophrenia and schizoaffective disorder.
Pros
Fixed-dose extended-release tablet with no titration period required
Long-acting injectable options offer monthly, 3-month, or 6-month dosing
Renal dose adjustments allow tailored dosing for kidney impairment
Approved specifically for schizoaffective disorder, an indication Risperdal lacks
Cons
Narrower FDA approval, without bipolar or autism-related indications
Carries a specific QT-prolongation warning requiring caution with other drugs
Roughly $400 to $4,200 per month without insurance, higher than Risperdal
Newer drug with a shorter track record, approved in 2006 versus 1993
Common Symptoms and Related Diseases You Can Explore
Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.